Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics targeting the TGF-beta family of proteins for disorders including neuromuscular diseases and blood disorders. Its lead candidate rinvatercept (KER-065) targets DMD and ALS, while elritercept (KER-050) targets cytopenias in MDS and myelofibrosis. In December 2024, Keros licensed elritercept to Takeda Pharmaceuticals for worldwide development outside of mainland China, Hong Kong, and Macau.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001664710-26-000018 | EDGAR | 105K words |
| 2025-02-26 | 2024-12-31 | 0001664710-25-000018 | EDGAR | 106K words |
| 2024-02-28 | 2023-12-31 | 0001664710-24-000017 | EDGAR | 102K words |
| 2023-03-03 | 2022-12-31 | 0001664710-23-000021 | EDGAR | 101K words |
| 2022-03-09 | 2021-12-31 | 0001664710-22-000011 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001664710-21-000018 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-03 | 2026-06-30 | 0001664710-26-000049 | EDGAR | 66K words |
| 2025-11-05 | 2025-09-30 | 0001664710-25-000089 | EDGAR | 68K words |
| 2025-08-06 | 2025-06-30 | 0001664710-25-000070 | EDGAR | 67K words |
| 2025-05-06 | 2025-03-31 | 0001664710-25-000046 | EDGAR | 65K words |
| 2024-11-06 | 2024-09-30 | 0001664710-24-000091 | EDGAR | 62K words |
| 2024-08-07 | 2024-06-30 | 0001664710-24-000068 | EDGAR | 61K words |
| 2024-05-08 | 2024-03-31 | 0001664710-24-000039 | EDGAR | 59K words |
| 2023-11-06 | 2023-09-30 | 0001664710-23-000066 | EDGAR | 65K words |
| 2023-08-07 | 2023-06-30 | 0001664710-23-000050 | EDGAR | 65K words |
| 2023-05-04 | 2023-03-31 | 0001664710-23-000030 | EDGAR | 60K words |
| 2022-11-03 | 2022-09-30 | 0001664710-22-000056 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001664710-22-000040 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-28 | 0001664710-26-000056 | EDGAR | 1K words |
| 2026-09-08 | 0001664710-26-000053 | EDGAR | 1K words |
| 2026-08-03 | 0001664710-26-000050 | EDGAR | 1K words |
| 2026-08-03 | 0001664710-26-000048 | EDGAR | 2K words |
| 2026-07-30 | 0001664710-26-000043 | EDGAR | 1K words |
| 2026-07-22 | 0001664710-26-000038 | EDGAR | 1K words |
| 2026-03-09 | 0001664710-26-000024 | EDGAR | 1K words |
| 2026-03-04 | 0001664710-26-000021 | EDGAR | 1K words |
| 2026-03-04 | 0001664710-26-000017 | EDGAR | 2K words |
| 2026-02-26 | 0001664710-26-000008 | EDGAR | 1K words |
187 total filings indexed. 159 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001664710 |
| Ticker | KROS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.kerostx.com |
| Listed | 2020-04-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KROS (~200 tokens, structured JSON with cryptographic provenance)